Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor Repopulating Cell Transcriptome reveals Specific Cell Surface Biomarkers and Signaling Pathways

ABSTRACT: Tumor Repopulating Cell Transcriptome reveals Specific Cell Surface Biomarkers and Signaling Pathways

PROVIDER: PRJNA541001 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9007924.fastq.gz	Fastqsanger.gz
	SRR9007925.fastq.gz	Fastqsanger.gz
	SRR9007926.fastq.gz	Fastqsanger.gz
	SRR9007927.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Tumor Repopulating Cell Transcriptome reveals Specific Cell Surface Biomarkers and Signaling Pathways

Project description:Cancer metastasis is the most deadly stage in cancer progression. Despite significant efforts over the last few decades, it remains elusive why only a very small fraction of tumorigenic cancer cells is able to generate metastatic colonization. Recently, we have shown that mechanically selected tumor-repopulating cells (TRCs), a highly tumorigenic subpopulation of mouse melanoma cells, can grow in 3D soft fibrin gels. However, the novel cell surface biomarkers and gene regulatory features of TRCs remain largely unknown. Here, we utilized RNA-sequencing method that uses next-generation sequencing (NGS) techniques for whole transcriptome profiling to elucidate novel cell surface biomarkers and active gene regulatory features. RNA-sequencing data was utilized in DAVID for identification of differentially expressed clusters of genes, including cell adhesion cluster. This allowed us to identify novel cell surface biomarkers such as Col2a1, NCAM1, F11R, and Negr1. We have validated the expression of these genes by real-time qPCR. Among the biomarkers, expression level of Col2a1 was found to be low in TRCs but 20 fold higher compared to parental B16F1 cells, thus making the marker very specific for TRCs. Our immunofluorescence microcopy study also shows high expression of Col2a1 in TRCs compared with parental B16F1 cells. KEGG pathway analysis showed JAK/STAT pathway, hypoxia, and Akt3 pathway to be highly active in TRCs. In addition, aerobic glycolysis pathway was found to be very active, indicating a typical Warburg effect of highly tumorigenic cells. Together, our study revealed novel and specific biomarkers of melanoma TRCs and their cryptic cell signaling pathways. Future studies will uncover if perturbation of these pathways can successfully neutralize TRCs.

2020-10-22 | GSE130697 | GEO

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

Project description:The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell malignancy models, revealing unexpected biological signatures unique to malignant plasma cells. We next integrate our proteomic dataset with existing transcriptome databases, nominating CCR10 and TXNDC11 as possible monotherapeutic targets and CD48 as a promising co-target for increasing avidity of BCMA-directed cellular therapies. We further identify potential biomarkers of resistance to proteasome inhibitors and lenalidomide including changes in CD53, EVI2B, CD10, and CD33. Comparison of short-term treatment with chronic resistance delineates large differences in surface proteome profile under each type of drug exposure. Finally, we develop a miniaturized version of the surface proteomics protocol and present the first surface proteomic profile of a primary plasma cell sample. Our dataset provides a unique resource to advance the biological, therapeutic, and diagnostic understanding of myeloma.

2021-12-10 | GSE160572 | GEO

Molecular characterization of pancreatic neuroendocrine tumor tissue: characterization of altered pathways and potential non-invasive biomarkers

Project description:The study aimed to identify potential non-invasive biomarkers for pancreatic neuroendocrine tumours (PanNETs) through transcriptomic profiling of various tissue samples. The analysis encompassed samples from non-functional PanNETs (NF-PanNETs), insulinomas, and adjacent tumour tissues. In tumor vs. tumors adjacent pancreatic tissues differential expression analysis we identified 1210 differentially expressed genes (DEGs). Further pathway enrichment analysis revealed a multitude of overrepresented signaling pathways related to cell proliferation, survival and tumorigenesis. Notable findings were Beta-catenin independent and TCF dependent WNT signaling pathways, MAPK1/MAPK3 signaling and PIP3 activates AKT signaling. Amongst the list of DEGs we also identified 28 upregulated genes encoding for cell surface proteins and 24 upregulated genes encoding for cancer associated secretome proteins. Since the products of these genes are found in the bloodstream, there is a potential for further testing of these markers as biomarkers for liquid biopsy assay. Overall, the findings have underscored the promise of transcriptomic landscape analysis in identifying PanNET-specific non-invasive biomarkers and uncovering potential therapeutic targets.

2025-03-12 | GSE281039 | GEO

Pathways to New Biomarkers in Recurrent Abdominal Pain in Children

Project description:Pathways to New Biomarkers in Recurrent Abdominal Pain in Children

| PRJNA579704 | ENA

Pathways to New Biomarkers in Recurrent Abdominal Pain in Children

Project description:Pathways to New Biomarkers in Recurrent Abdominal Pain in Children

| PRJNA579705 | ENA

Urban surface water entry pathways of micropollutants and antibiotic resistance

Project description:Urban surface water entry pathways of micropollutants and antibiotic resistance

| PRJEB84422 | ENA

RNA-seq of mouse brain tissue repopulating microglia in response to traumatic brain injury

Project description:We assessed the roles of repopulating microglia in brain repair using mouse models. In this project, we show that removal of microglia from the mouse brain has little impact on the outcome of TBI but inducing the turnover of these cells through either pharmacologic or genetic approaches can yield a neuroprotective microglial phenotype that profoundly aids recovery. As a part of the experimental approaches, we perform bulk RNA sequencing experiments to unbiasedly profile the transcriptome of repopulating microglia. We identified unique gene signatures from repopulating microglia cells and infer how these cells modulate the microenvironment after TBI.

2020-02-15 | E-MTAB-8765 | biostudies-arrayexpress

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

Project description:Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

| PRJNA673624 | ENA

Sub-populations in the mammary repopulating units

Project description:Elucidating the top of the mammary epithelial cell hierarchy is highly important for understanding its regeneration capabilities and identifying target cells for transformation. Aiming for enriched mammary epithelial stem cell population, CD200highCD200R1high epithelial cells were identified. These cells represent ~50% of the mammary repopulating units (MRUs, CD49fhigh CD24med ) and termed MRUCD200/CD200R1. Gene expression of these cells was compared to all other MRU cells, termed MRUnot CD200/CD200R1, as well as individual CD200+ population (MRU-CD200R1-) and CD200R1+ population (MRU-CD200-).

2018-12-21 | GSE93961 | GEO

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

Project description:The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell malignancy models, revealing unexpected biological signatures unique to malignant plasma cells. We next integrate our proteomic dataset with existing transcriptome databases, nominating CCR10 and TXNDC11 as possible monotherapeutic targets and CD48 as a promising co-target for increasing avidity of BCMA-directed cellular therapies. We further identify potential biomarkers of resistance to proteasome inhibitors and lenalidomide including changes in CD53, EVI2B, CD10, and CD33. Comparison of short-term treatment with chronic resistance delineates large differences in surface proteome profile under each type of drug exposure. Finally, we develop a miniaturized version of the surface proteomics protocol and present the first surface proteomic profile of a primary malignant plasma cell sample of MM patient. Our dataset provides a unique resource to advance the biological, therapeutic, and diagnostic understanding of myeloma.

2022-05-27 | PXD022482 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data